Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
- Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet
Basel, 12 September 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data from the Phase III IMpower110 study evaluating Tecentriq® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). The study met its primary endpoint in an interim analysis showing that Tecentriq monotherapy demonstrated a statistically significant overall survival (OS) benefit in people with high PD-L1 expression (TC3/IC3-WT), compared with chemotherapy alone. Safety for Tecentriq appeared to be consistent with its known safety profile and no new safety signals were identified. The study will continue to final analysis for patients with lower levels of PD-L1 expression.
“We are encouraged that Tecentriq monotherapy has shown a significant survival benefit over chemotherapy as an initial treatment in people with squamous or non-squamous non-small cell lung cancer with high PD-L1 expression,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “These findings reinforce the potential of Tecentriq to play an important role in the treatment of multiple forms of lung cancer, and we look forward to discussing these data with health authorities.”
Roche will now submit these data to global health authorities, including the FDA and EMA, and will discuss how best to bring this option to patients as quickly as possible. These data will be presented at an upcoming medical congress.
Currently, Roche has nine Phase III lung cancer studies underway evaluating Tecentriq as a monotherapy or in combination with other medicines across different types of lung cancer. Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies, across lung, genitourinary, skin, breast, gastrointestinal, gynaecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.
About the IMpower110 study
IMpower110 is a Phase III, randomised, open-label study to evaluate the efficacy and safety of Tecentriq monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in programmed death-ligand 1 (PD-L1)-selected, chemotherapy-naive participants with advanced non-squamous or squamous NSCLC without ALK or EGFR mutations (Wild-Type or WT).
A total of 572 people (555 WT) were enrolled and were randomised 1:1 to receive:
- Tecentriq monotherapy, until loss of clinical benefit (as assessed by the investigator) or
- Cisplatin or carboplatin (per investigator discretion) combined with either pemetrexed (non-squamous) or gemcitabine (squamous), followed by maintenance therapy with pemetrexed alone (non-squamous) or best supportive care (squamous) until disease progression, unacceptable toxicity or death.
The primary efficacy endpoint is OS by PD-L1 subgroup (TC3/IC3-WT; TC2/3/ IC2/3-WT; and TC1,2,3/IC1,2,3-WT), as determined by the SP142 assay test. Key secondary endpoints include investigator-assessed progression-free survival (PFS), objective response rate (ORR) and duration of response (DoR).
Lung cancer is the leading cause of cancer death globally 1. Each year 1.76 million people die as a result of the disease; this translates into more than 4,800 deaths worldwide every day 1. Lung cancer can be broadly divided into two major types: NSCLC and small cell lung cancer. NSCLC is the most prevalent type, accounting for around 85% of all cases 2. NSCLC comprises non-squamous and squamous-cell lung cancer, the squamous form of which is characterised by flat cells covering the airway surface when viewed under a microscope 2.
About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is a cancer immunotherapy (CIT) that has the potential to be used as a foundational combination partner with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. The development of Tecentriq and its clinical programme is based on our greater understanding of how the immune system interacts with tumours and how harnessing a person’s immune system combats cancer more effectively.
Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies in various forms of non-small cell and small cell lung cancer, certain types of metastatic urothelial cancer, and in PD-L1-positive metastatic triple-negative breast cancer.
About Roche in cancer immunotherapy
For more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer.
By applying our seminal research in immune tumour profiling within the framework of the Roche-devised cancer immunity cycle, we are accelerating and expanding the transformative benefits with Tecentriq to a greater number of people living with cancer. Our cancer immunotherapy development programme takes a comprehensive approach in pursuing the goal of restoring cancer immunity to improve outcomes for patients.
To learn more about the Roche approach to cancer immunotherapy please follow this link:
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 GLOBOCAN 2018; Lung Cancer: Estimated cancer incidence, mortality and prevalence worldwide. World Health Organization. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed September 2019.
 American Cancer Society; What Is Non-Small Cell Lung Cancer? [Internet]: Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html Accessed September 2019.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
EVS Broadcast Equipment reports update of share buyback program20.1.2020 18:00:00 CET | Press release
Publication on January 20, 2020, 6.00pm CET Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on October 24, 2018, took place between January 14, 2020 and January 17, 2020. Date Number of shares acquired Average price (EUR) Total (EUR) 14/01/2020 1,000 21.1750 21,175 15/01/2020 500 21.1250 10,563 16/01/2020 750 21.0833 15,812 17/01/2020 500 21.1000 10,550 As of January 17, 2020, and since the start of the buyback program, EVS has bought 324,282 shares at an average price of EUR 20,9751, representing in total EUR 6,801,832. After aforementioned transactions the total number of own shares amounts now to 402,930 shares as of January 17, 2020 (including 93,144 shares already held by the company before the start of the sha
NNIT A/S: 1/2020 NNIT releases preliminary figures for 2019 and outlook for 202020.1.2020 17:09:00 CET | Press release
Company announcement 01/2020 NNIT releases preliminary figures for 2019 and preliminary guidance for 2020 In connection with reporting the collected consensus information back to analysts, the preliminary, unaudited figures were unfortunately disclosed by a mistake. Please find further information below. Revenue increase of 1.7% and an operating profit margin of 7.8% before restructuring costs (8.0% in constant currencies) in 2019. Performance highlights for the fourth quarter of 2019 and guidance: Revenue decreased by 2.7% in Q4 2019 compared to Q4 2018 driven by a 27% decline from the Novo Nordisk Group. This was partly countered by growth from international life sciences (35%), finance (24%), public (18%) and Danish life sciences (5.9%) Excluding business from Novo Nordisk Group revenue increased 13% (8.4% organic) in Q4 2019. The share of NNIT’s revenue from clients outside the Novo Nordisk Group increased to 70% in Q4 2019 from 61% in Q4 2018 Gross profit decreased by 13% in Q4 20
Issuance schedule of Arion Bank for 202020.1.2020 16:59:00 CET | Press release
Attached is Arion Bank´s issuance scheadule for the year 2020 For further information please contact Arion Bank’s Investor Relations at email@example.com or Theodor Fridbertsson, Head of Investor Relations, +354 856 6760. Attachment Issuance schedule for Arion Bank 2020
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease20.1.2020 15:32:00 CET | Press release
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population Approval is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad range of SPMS patients, showing Mayzent significantly reduced the risk of disease progression, including physical disability and cognitive decline2,3 The digital press release with multimedia content can be accessed here: https://novartis.gcs-web.com/Novartis-announces-EU-approval-of-Mayzent-siponimod-for-adult-patients-with-secondary-progressive-multiple-sclerosis-SPMS-with-active-disease Basel, January 20, 2020 — Novartis today announced the European Commission (EC) has approved Mayzent® (siponimod) for the treat
Stolt-Nielsen Limited Presentation and Conference Call for the Fourth Quarter and Full Year of 2019 Results20.1.2020 14:00:00 CET | Press release
LONDON, January 20, 2020 – Stolt-Nielsen Limited (Oslo Børs: SNI) will hold a presentation and conference call to discuss the Company’s unaudited results for the fourth quarter and full year of 2019 on Thursday, January 30, 2020 at 13:00 CET (07:00 EDT, 12:00 BST) in the auditorium at Swedbank, Filipstad Brygge 1, 0115 Oslo, Norway. The presentation and call will be hosted by: - Mr. Niels G. Stolt-Nielsen - Chief Executive Officer, Stolt-Nielsen Limited - Mr. Jens F. Grüner-Hegge - Chief Financial Officer, Stolt-Nielsen Limited Those who wish to participate may dial in local numbers +44 (0) 8445718892 in the UK, +47 2396 0264 in Norway, and +1 6315107495 in the US or the international number +44 (0) 2071 928000 and quote the conference code: 7375857. Phone lines will open 10 minutes before the call. A live audio webcast of the presentation may be accessed via the Stolt-Nielsen website at: https://www.stolt-nielsen.com/en/investors/reports-presentations/ For additional information pleas
Valmet receives the best A rating in CDP's climate program ranking for the second consecutive year20.1.2020 10:00:00 CET | Press release
Valmet Oyj's press release on January 20, 2020 at 11:00 a.m. EET Valmet has been recognized for its actions and strategy to mitigate climate change by receiving the best A rating in CDP's climate program ranking for the second consecutive year. CDP's evaluation is based on the company's 2019 disclosure about its actions in the last reporting year to develop the low-carbon technology and solutions, cut emissions and mitigate climate risks. Valmet has a systematic program to reduce CO2 emissions in its own operations with a focus on more sustainable transportation, energy-efficiency improvements and process optimization. Valmet is actively developing new ways to improve energy, water and material efficiency and reduction of emissions of its solutions during customer use phase and to bring new innovations to the market. “We are proud to receive this recognition for our continuous work to contribute to the climate change mitigation. CO2 emissions need to be reduced rapidly in the coming ye